These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 14750508)

  • 21. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia.
    Chou KR; Chen R; Lee JF; Ku CH; Lu RB
    Int J Nurs Stud; 2004 Mar; 41(3):321-30. PubMed ID: 14967189
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extinguishing the rewarding value of smoke cues: pharmacological and behavioral treatments.
    Rose JE; Behm FM
    Nicotine Tob Res; 2004 Jun; 6(3):523-32. PubMed ID: 15203786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects on smoking cessation: naltrexone combined with a cognitive behavioral treatment based on the community reinforcement approach.
    Roozen HG; Van Beers SE; Weevers HJ; Breteler MH; Willemsen MC; Postmus PE; Kerkhof AJ
    Subst Use Misuse; 2006; 41(1):45-60. PubMed ID: 16393735
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of adolescent smokers with the nicotine patch.
    Hanson K; Allen S; Jensen S; Hatsukami D
    Nicotine Tob Res; 2003 Aug; 5(4):515-26. PubMed ID: 12959789
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Smoking reduction in the Lung Health Study.
    Hughes J; Lindgren P; Connett J; Nides M;
    Nicotine Tob Res; 2004 Apr; 6(2):275-80. PubMed ID: 15203800
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoking cessation program and CYP2A6 polymorphism.
    Ozaki S; Oyama T; Isse T; Kagawa N; Uramoto H; Sugio K; Yasumoto K; Kono K; Kawamoto T
    Front Biosci; 2006 Sep; 11():2590-7. PubMed ID: 16720336
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the nicotine patch for relief of craving and withdrawal 7-10 weeks after cessation.
    Shiffman S; Khayrallah M; Nowak R
    Nicotine Tob Res; 2000 Nov; 2(4):371-8. PubMed ID: 11197318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Opioid antagonists for smoking cessation.
    David S; Lancaster T; Stead LF
    Cochrane Database Syst Rev; 2001; (3):CD003086. PubMed ID: 11687036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sleep effects of a 24-h versus a 16-h nicotine patch: a polysomnographic study during smoking cessation.
    Staner L; Luthringer R; Dupont C; Aubin HJ; Lagrue G
    Sleep Med; 2006 Mar; 7(2):147-54. PubMed ID: 16458598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adherence to nicotine replacement patch therapy in cardiovascular patients.
    Wiggers LC; Smets EM; Oort FJ; Storm-Versloot MN; Vermeulen H; van Loenen LB; Peters RJ; de Haes HC; Legemate DA
    Int J Behav Med; 2006; 13(1):79-88. PubMed ID: 16503844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A preliminary investigation of naltrexone augmentation of bupropion to stop smoking with less weight gain.
    Toll BA; Leary V; Wu R; Salovey P; Meandzija B; O'Malley SS
    Addict Behav; 2008 Jan; 33(1):173-9. PubMed ID: 17587504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Smokers' expectancies for nicotine replacement therapy vs. cigarettes.
    Juliano LM; Brandon TH
    Nicotine Tob Res; 2004 Jun; 6(3):569-74. PubMed ID: 15203790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes.
    Meine TJ; Patel MR; Washam JB; Pappas PA; Jollis JG
    Am J Cardiol; 2005 Apr; 95(8):976-8. PubMed ID: 15820167
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clarification of SRNT workgroup guidelines for measures in clinical trials of smoking cessation therapies.
    Hughes JR; Benowitz N; Hatsukami D; Mermelstein RJ; Shiffman S
    Nicotine Tob Res; 2004 Oct; 6(5):863-4. PubMed ID: 15700922
    [No Abstract]   [Full Text] [Related]  

  • 35. The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.
    Cinciripini P; Wetter D; Tomlinson G; Tsoh J; De Moor C; Cinciripini L; Minna J
    Nicotine Tob Res; 2004 Apr; 6(2):229-39. PubMed ID: 15203796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.
    Rukstalis M; Jepson C; Strasser A; Lynch KG; Perkins K; Patterson F; Lerman C
    Psychopharmacology (Berl); 2005 Jun; 180(1):41-8. PubMed ID: 15682300
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twenty-four week maintenance treatment of cigarette smoking with nicotine gum, clonidine and naltrexone.
    Ahmadi J; Ashkani H; Ahmadi M; Ahmadi N
    J Subst Abuse Treat; 2003 Apr; 24(3):251-5. PubMed ID: 12810146
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Double-Blind Randomized Placebo-Controlled Trial of Oral Naltrexone for Heavy-Drinking Smokers Seeking Smoking Cessation Treatment.
    Kahler CW; Cioe PA; Tzilos GK; Spillane NS; Leggio L; Ramsey SE; Brown RA; O'Malley SS
    Alcohol Clin Exp Res; 2017 Jun; 41(6):1201-1211. PubMed ID: 28401564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical inquiries. What is the most effective nicotine replacement therapy?
    Diefenbacher LJ; Smith PO; Nashelsky J; Lindbloom E
    J Fam Pract; 2003 Jun; 52(6):492-4. PubMed ID: 12791233
    [No Abstract]   [Full Text] [Related]  

  • 40. High-dose transdermal nicotine and naltrexone: effects on nicotine withdrawal, urges, smoking, and effects of smoking.
    Rohsenow DJ; Monti PM; Hutchison KE; Swift RM; MacKinnon SV; Sirota AD; Kaplan GB
    Exp Clin Psychopharmacol; 2007 Feb; 15(1):81-92. PubMed ID: 17295587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.